In the drive to reduce cash burn rates, life science companies are increasingly becoming virtual - owning the IP, but not having any other functional activities in house. They increasingly shed office and laboratory space of their own and depend on outsourcing services from R&D, production, staffing and legal to licensing and taking new products to market.
Additional Information: http://www.baybio.org/events/details/executive-series-05182011-going-vir...
This CEO roundtable discussion will focus on several case studies involving different degrees of virtualization. A discussion with veteran CEOs will contemplate the following questions:
Strategy of company development: what factors to consider when contemplating your business model: growing your own company infrastructure vs. going virtual (including degrees of virtualization). Strategy of how to transition from one model to another. Implications for VC’s, board and staff;
What competency to maintain internally in order to manage outsourced services correctly;
How do you know that you are outsourcing to the right providers and how do you know you are getting the right advice;
Company culture: how to preserve it and now not to lose your ability to affect R&D through corporate culture;
Role of your clinical advisory board; regulatory, marketing and commercial strategy.
Chief Executive Officer, Clerigen Inc.
Steven R. Deitcher, M.D.
President & Chief Executive Officer, Talon Therapeutics, Inc.
President and Chief Executive Officer, Neuraltus Pharmaceuticals, Inc.
Chief Financial Officer, Aradigm Corporation
Jay P. Shepard
President and CEO, NextWave Pharmaceuticals